Market Overview

Jazz Pharma Posts 12% Increase in Q4 Profit, But Still Misses; Guides Above the Street

Related JAZZ
ImmunoGen Higher After Announcing Strategic Collaboration With Jazz Pharma
Benzinga's Top Upgrades, Downgrades For August 28, 2017

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported fourth quarter 2013 results, missing both earnings per share and revenue analyst estimates. Shares are down 7 percent to $162.70 following the report.

The company reported revenue of $235.8 million versus the Street estimate of $238.1 million. Earnings per share of $1.72 missed the analyst consensus estimate of $178. GAAP income from continuing operations for the fourth quarter was $0.90.

Jazz provided full year 2014 guidance of $1.1-$1.16 billion for revenue, slightly above analyst estimates at $1.080 billion. The company expects $8.00-$8.25 in earnings per share for 2014, versus the analyst estimate of $8.07.

While Jazz fell short of analyst expectations, CEO Bruce Cozadd CEO assured the company “delivered strong top-line growth, generated significant cash flow and executed on the corporate development strategy.”

In a separate press release, Jazz announced CFO Kathryn Falberg resigned from the company. Matthew Young was named as replacement.

Posted-In: Earnings News Guidance Management


Related Articles (JAZZ)

View Comments and Join the Discussion!

Partner Center